Does DexCom Inc (DXCM) have an economic moat?

MoatScan AI rates DexCom Inc (DXCM) 62/100 for moat strength, assessed across five sources of competitive advantage: network effects, switching costs, intangible assets, cost advantages and efficient scale. DexCom is one of the strongest franchises in diabetes technology, but its moat is best described as narrow rather than wide.

What is DexCom Inc's moat score?

DexCom Inc (DXCM) has a moat score of 62/100. The score is a weighted average of five pillar ratings: network effects, switching costs, intangible assets, cost advantages, and efficient scale. A higher score means the competitive advantages MoatScan AI identifies are wider and more durable.

How does DXCM's share price compare with its estimated fair value?

MoatScan AI estimates DXCM's intrinsic value with a discounted cash flow (DCF) model and shows how that estimate compares with the market price at the time of analysis. The estimate updates with each new financial analysis and is a research estimate, not a recommendation.

What is DexCom Inc's fair value estimate?

MoatScan AI derives DexCom Inc's (DXCM) fair value per share from a discounted cash flow (DCF) model built on the company's reported financials, analyst growth forecasts, and a discount rate reflecting its cost of capital. The Financial Analysis tab shows the estimate alongside every assumption behind it.

Back to Database

DXCM$83.34

DexCom Inc

Last Updated

Sep 12, 2026about 1 month ago

Moat & Trend

Management

AI Impact

Competitive Radar

Moat Score

62/100

Executive Summary

DexCom is one of the strongest franchises in diabetes technology, but its moat is best described as narrow rather than wide. The company benefits from a trusted brand, clinical credibility, and product integration that makes its CGM systems part of recurring care routines. Its ecosystem is deepening through partnerships with insulin pumps and digital health platforms, and the G7 plus 15-day offerings reinforce a reputation for accuracy and convenience. Still, the market remains competitive, especially against Abbott, and customers can switch when reimbursement or pricing shifts. DexCom’s newer OTC Stelo product broadens the addressable market and supports a positive moat trajectory. The business looks durable, but the source of advantage is execution, not a protected monopoly or irreplaceable network.

Network Effects

Shared glucose data loop

Pillar Strength

5.5/10

DexCom has a modest ecosystem effect rather than a true self-reinforcing network. The value of its CGM rises when glucose data are shared with caregivers, clinicians, and insulin-delivery partners, and that is reinforced by integrations with Tandem, Insulet, Welldoc, and Oura. Share and Follow make monitoring more social, and more connected users can increase daily engagement. Still, the core product does not become dramatically more valuable simply because more people use it, and most partners can multi-home across devices. Competitors can replicate many of the integrations, so the network is real but only mildly protective.

Switching Costs

Workflow embedded monitoring

Pillar Strength

7.5/10

Switching is meaningfully inconvenient for patients already embedded in DexCom workflows. Users learn a specific app, alarm behavior, sensor insertion routine, and calibration-free experience, while clinicians build familiarity with its reporting and time-in-range metrics. For diabetes patients using automated insulin delivery, moving away from DexCom can also break pump compatibility or require revalidation of settings and insurance approvals. Those frictions are substantial, especially for long-term users. However, they are not permanent lock-in: patients can and do switch based on price, coverage, or perceived accuracy, so the cost is high enough to matter but not high enough to be impregnable.

Intangible Assets

Accuracy-led brand trust

Pillar Strength

8/10

DexCom's strongest intangible asset is trust in accuracy and reliability, backed by successive FDA-cleared product generations and a reputation for leading performance. The G7 and 15-day versions reinforce that brand, and the Stelo OTC launch extends recognition beyond insulin-treated diabetes. Physicians, payers, and patients often view CGM accuracy as a safety issue, so a strong brand in this category carries more weight than in ordinary consumer health products. Even so, the advantage is partly execution-based rather than legally exclusive. Competitors can improve sensors and win coverage if they match accuracy, so the brand is durable but not unassailable.

Cost Advantages

Scale helps margins

Pillar Strength

5.5/10

DexCom enjoys some manufacturing and development scale advantages from a global installed base, a large data and software stack, and multiple production sites. Higher volume should lower sensor unit costs over time and spread R&D, regulatory, and commercialization spending across a broader revenue base. That said, the company is not a low-cost commodity producer; sensor economics remain sensitive to reimbursement, yield, and distribution costs, and Abbott is also a very large, well-capitalized competitor with its own scale. DexCom therefore has a real but moderate cost edge. The gap is enough to support margins in good periods, yet not so large that rivals cannot compete effectively.

Efficient Scale

Oligopoly, not monopoly

Pillar Strength

4.5/10

The CGM market has a limited number of serious players, but it does not behave like a classic natural monopoly. Abbott, DexCom, and Medtronic can all profitably target different patient segments and reimbursement pathways, while smaller specialists can still emerge in niches. Regulatory requirements, clinical evidence, and payer adoption create entry hurdles, but the market is large enough to support more than one winner, especially in the most clinically demanding subsegments. That makes efficient scale only a partial defense. DexCom benefits from being one of a few scaled brands, yet the presence of strong alternatives means rivals can still gain share rather than being structurally blocked from the market.

Moat Type & Trend

Why this company earns its moat rating, and where the moat is heading

Moat Type

Narrow Moat

Trend

Positive

Why This Rating

DexCom merits Narrow Moat because its advantage is real and persistent, but it is concentrated in a single product category and depends on continual execution rather than structural foreclosure. The company has strong clinician trust, embedded workflows, and a premium reputation for accuracy, yet patients, payers, and pump partners can still move to Abbott or other options when coverage or pricing changes. Twenty years from now DexCom is likely still a meaningful CGM brand, but not necessarily one with unchallenged pricing power or an insurmountable ecosystem. That durability is meaningful, but not wide enough to imply a truly protected franchise.

Why This Trend

The moat trend is positive because DexCom keeps expanding from premium insulin-dependent users into broader monitoring through Stelo, while G7 and the 15-day version strengthen its accuracy lead. Deeper ties with pump makers and consumer-health partners make its data more embedded in daily care, which should raise stickiness over time. The trend would turn stable or negative if Abbott’s pricing or coverage advantage starts winning back share, or if DexCom’s next product cycle stops extending performance and integration leadership.

Management Quality Assessment

Evaluating leadership track record, capital allocation, and governance

Verdict

Strong

DexCom’s management has a strong operating track record, led for a decade by Kevin Sayer, who oversaw revenue growth from roughly $250 million to more than $4.6 billion and helped build category leadership through repeated product firsts. Capital allocation has been disciplined: the company avoided dividend drag, prioritized organic growth, used only tuck-in acquisitions, and has repurchased shares aggressively while ROIC improved from negative levels to above 20% in recent years. The business is now transitioning to long-time insider Jake Leach, suggesting continuity rather than a reset. Insider ownership appears modest and not clearly rising. Executive pay is high, but mostly equity/performance-based and broadly supported by operating results; no major governance red flags stand out.

Key Highlights

Kevin Sayer led DexCom from 2015 through 2025, during which revenue expanded from about $250 million to over $4.6 billion and the company became the clear CGM leader.
ROIC improved sharply from a negative -7.97% in 2018 to above 21% in 2020 and 2022, indicating much better capital efficiency under current management.
DexCom has favored organic growth and small tuck-in acquisitions over transformational M&A, which has helped preserve focus in the core CGM franchise.
The company has been active on buybacks, including a $600 million repurchase in Q2 2026 and a $1 billion authorization through June 2027.
Governance appears sound: the board is mostly independent, uses a lead independent director, and has proxy access and declassified-board provisions; insider ownership remains relatively small.

AI Impact Assessment

Evaluating how AI strengthens or disrupts existing moat pillars

Net verdict: Net Reinforcer. AI mostly amplifies DexCom’s existing moat rather than creating a new one. The strongest pillars are its proprietary longitudinal glucose data, FDA-cleared sensor algorithms, and trusted brand/ecosystem integrations with pumps and digital therapeutics; AI can improve personalization, engagement, and internal productivity, but those gains are largely defensive because the core CGM hardware, accuracy, and regulatory barriers still drive the franchise. Facts support that DexCom has launched a proprietary generative-AI platform and used automation to save substantial labor time. The key uncertainty is whether AI-driven insights materially improve adherence and outcomes enough to justify premium pricing, or whether rivals quickly match the software layer and shift competition back to sensor performance and reimbursement.

AI Opportunity Highlights

6 / 10

DexCom’s millions of-user longitudinal glucose dataset gives its models a proprietary training base that rivals cannot quickly assemble.
The company’s generative-AI glucose insights can deepen lock-in by linking glucose readings with sleep, activity, and diet inside its own app ecosystem.
AI-enabled automation has reportedly saved about 200,000 hours, improving engineering, documentation, and regulatory throughput without adding headcount.
AI can make DexCom a stronger data layer for insulin-pump and digital-therapeutic integrations, raising switching costs across connected diabetes care.

AI Threat Highlights

4 / 10

Abbott and Medtronic compete aggressively in CGM, so AI features are likely to be copied quickly and may not support durable differentiation.
The consumer-facing coaching layer is increasingly a software problem, which lowers barriers for mobile-first or AI-native entrants to mimic insight features.
Non-invasive and adjacent sensor startups can use AI to narrow the perceived value gap if accuracy and convenience improve enough to weaken DexCom’s hardware edge.

Sign in to see the full analysis

The Strategic Factor Breakdown, Management Quality Assessment, and AI Impact Assessment are available to registered users — it's free.

Last Updated

Sep 11, 2026about 1 month ago

Target Price

Analyst Consensus

FAIR VALUE

Financial Strength

Financial Score

79/100

Executive Summary

DexCom’s standout strength is its robust and increasingly efficient cash engine, which underpins a fundamentally solid financial profile. Revenue rose from $2.45B in FY2021 to $4.66B in FY2025, with TTM at $4.97B, while net income climbed to $1.00B and operating margin expanded to 22.9%, despite some gross margin compression and heavier SG&A/R&D spend. The balance sheet remains healthy, with $1.95B of cash and short-term investments, net cash of $548.6M, and debt reduced to $1.40B, though near-term cash has softened and accrued expenses are rising. Cash flow is especially strong, with operating cash flow at $1.75B TTM and free cash flow at $1.41B. Growth is moderating but still constructive, and improving returns, leverage, and analyst expectations reinforce a durable profile overall, consistent with the company’s 8/10 to 8.5/10 ratings.

Income Statement

Revenue · Margins · Profitability

Section Score

8/10

DexCom shows strong multi-year growth, with revenue rising from $2.45B in FY2021 to $4.66B in FY2025 and TTM reaching $4.97B, while net income expanded from $217M to $836M and TTM to $1.00B. Growth is still healthy, though revenue acceleration has been uneven and appears to be normalizing. Profitability is solid: operating margin improved from 10.9% to 19.6%, and TTM reached 22.9%, offsetting some gross margin compression from 68.6% to 60.1%. Earnings appear durable, but FY2025 pretax income benefited from a large $82M other-income swing. FCF is excellent at $1.08B TTM. Main flags are rising SG&A/R&D and moderating gross margin.

Financials are in millions USD unless otherwise specified

Metric	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	TTM
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Jun 30, 2026
Revenue	2,449	2,910	3,622	4,033	4,662	4,969
Revenue Growth	27.08%	18.84%	24.49%	11.34%	15.60%	15.54%
Net Income	216.9	341.2	541.5	576.2	836.3	999.7
Net Income Growth	-60.54%	57.31%	58.70%	6.41%	45.14%	74.93%
Profit Margin	8.86%	11.73%	14.95%	14.29%	17.94%	20.12%

Data as of Jun 30, 2026

Balance Sheet

Assets · Liabilities · Equity

Section Score

7/10

DexCom’s balance sheet remains solid, with current assets of about $4.09B versus current liabilities of $2.36B, leaving working capital near $1.73B. Liquidity is supported by $1.95B of cash and short-term investments, though that total has declined from roughly $2.58B in FY2024 and cash growth is negative in the latest period. Total assets of $6.46B exceed total liabilities of $3.83B by a comfortable margin, and shareholders’ equity has improved to $2.62B from $2.10B in FY2024. Debt is manageable at $1.40B, down sharply from prior years, and net cash remains positive at $548.6M. The main watchpoint is rising accrued expenses and a softer near-term cash position.

Financials are in millions USD unless otherwise specified

Metric	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Current
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Jun 30, 2026
Total Current Assets	3,684	3,669	4,426	4,301	4,033	4,087
Total Assets	4,933	5,392	6,265	6,485	6,340	6,455
Total Current Liabilities	720.8	1,839	1,556	2,932	2,143	2,358
Total Liabilities	2,891	3,260	4,196	4,382	3,594	3,834

Data as of Jun 30, 2026

Cash Flow Statement

Operations · Investing · Financing

Section Score

8.5/10

DexCom shows strong and improving cash generation. Operating cash flow rose from $442.5M in FY2021 to $1.44B in FY2025, with TTM at $1.75B, well above the latest fiscal year. Free cash flow also expanded from $53.3M to $1.08B, and TTM reached $1.41B, supported by a healthy 23.11% FCF margin. Capex has remained meaningful at roughly $237M–$389M annually, suggesting continued reinvestment, but it has been covered comfortably by operating cash. Working capital swings were sometimes large, especially receivables and inventory, yet overall cash conversion improved. Capital returns were aggressive through repurchases and debt repayment, but the business still ended with positive net cash flow and no sign of cash strain.

Financials are in millions USD unless otherwise specified

Metric	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	TTM
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Jun 30, 2026
Operating Cash Flow	442.5	669.5	748.5	989.5	1,441	1,749
Operating Cash Flow Growth	-6.96%	51.30%	11.80%	32.20%	45.60%	77.05%
Free Cash Flow	53.3	304.7	511.9	630.7	1,077	1,405
Free Cash Flow Growth	-80.73%	471.67%	68.00%	23.21%	70.79%	146.15%
Free Cash Flow Margin	2.18%	10.47%	14.13%	15.64%	23.11%	28.27%

Data as of Jun 30, 2026

Key Ratios

Liquidity · Leverage · Efficiency · Returns

Section Score

8/10

DexCom shows a generally strong operating profile with a few balance-sheet nuances. Liquidity has come down from exceptionally high levels in FY2021, but the current ratio of 1.73 and quick ratio of 1.37 still indicate comfortable short-term coverage. Leverage has improved meaningfully, with debt/equity falling from 1.06 to 0.53 and debt/EBITDA dropping from 5.4 to 0.97, suggesting a more manageable capital structure. Efficiency is trending better, as asset turnover rose from 0.53 to 0.72 and inventory turnover improved modestly. Profitability is a clear strength: ROE, ROA, ROIC, and ROCE have all expanded steadily, pointing to consistently stronger returns on capital.

Ratios are dimensionless unless otherwise noted

Metric	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Current
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Sep 11, 2026
Debt / Equity Ratio	1.06	1.01	1.25	1.23	0.51	0.53
Quick Ratio	4.51	1.74	2.38	1.24	1.54	1.37
Current Ratio	5.11	2	2.84	1.47	1.88	1.73
ROEReturn on Equity (ROE)	11.21%	16.35%	25.78%	27.63%	34.50%	38.49%
ROAReturn on Assets (ROA)	3.60%	4.74%	6.41%	5.88%	8.89%	10.33%
ROICReturn on Invested Capital (ROIC)	18.50%	20.77%	24.24%	24.09%	32.94%	44.49%
ROCEReturn on Capital Employed (ROCE)	6.30%	11.00%	12.70%	16.90%	21.70%	27.80%

Data as of Sep 11, 2026

Growth

Revenue · EPS · Valuation · Estimates

Section Score

8/10

DexCom shows a transition from earlier high-growth expansion to a steadier compounding path. Revenue rose from $2.45B to $4.03B across the historical period, with growth slowing after a 2023 peak but staying healthy, then analysts expect a renewed mid-teens/low-teens pace to $5.80B by FY2027. EPS has been more uneven historically, moving from a sharp dip to solid improvement, and forecast growth from $2.09 to $3.12 suggests better earnings leverage than revenue growth alone. That implies margin expansion or operating discipline. Sentiment is clearly constructive: the consensus is Strong Buy, the $79 to $115 target range centers around $94, and coverage by 28 analysts supports solid confidence. The recommendation mix is stable to slightly improving, with no sell calls.

Third-party Analyst Price Targets

Low$79-5.21%

Median$94+12.79%

Average$94.12+12.93%

High$115+37.99%

Strong BuyConsensus rating and price targets published by third-party analysts. Not a MoatScan AI view.

28 analysts

Third-party Analyst Recommendation Trends

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	20	21	22	22	22	22
Buy	4	3	3	3	3	3
Hold	2	3	3	3	3	3
Sell	1	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	27	27	28	28	28	28

Forecast · Analyst Estimates

Revenue This Year5.23B

+12.19%from 4.66B

FY 2026

Revenue Next Year5.80B

+10.90%from 5.23B

FY 2027

EPS This Year· non-GAAP adj.2.66

+27.38%from 2.09

FY 2026

EPS Next Year· non-GAAP adj.3.12

+17.29%from 2.66

FY 2027

Historical · Reported Actuals

Metric	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	2.45B	2.91B	3.62B	4.03B	4.66B
Revenue Growth	+27.08%	+18.82%	+24.47%	+11.35%	+15.60%
EPS (GAAP diluted)	0.53	0.82	1.30	1.42	2.09
EPS Growth	-60.09%	+54.72%	+58.54%	+9.23%	+47.18%

Revenue in USD · EPS per share · Price targets in USD

Data as of Dec 31, 2025 · Forecast EPS is analyst non-GAAP adjusted; historical EPS is GAAP diluted — not directly comparable.

Fair Value Estimation

DCF · Model estimate vs. price +75.7% · Price below model estimate

AI Fair Value Estimate (DCF)

$146.45vs$83.34

Model estimate vs. price+75.7%

Price below model estimate

A discounted cash flow framework fits DexCom because the business is already cash-generative and its operating profile can be mapped with reasonable visibility through a multi-year growth and margin ramp. The projected free cash flow expansion, alongside EBITDA margins stabilizing in the mid-30s and capex staying disciplined relative to revenue, suggests improving conversion of growth into cash before growth naturally fades toward terminal assumptions.

AI Valuation Commentary

DCF is the right lens for DexCom because the company combines durable revenue growth with a visible path to rising free cash flow, making long-term cash generation more informative than near-term earnings alone. The valuation assumes a 6.4% discount rate, 4% terminal growth, 9.85% revenue CAGR, and a 34.01% average EBITDA margin, with capex held at 10.33% of revenue on average. Those inputs are the main sensitivities: a higher WACC, weaker margin durability, or slower terminal growth would pressure value. Against a current price of $83.34, the model’s $146.45 fair value implies a 75.73% margin of safety and supports an undervalued verdict. A bullish case requires sustained margin expansion; a bearish case follows if growth or cash conversion softens.

DCF Assumptions

WACC

6.4%

Weighted avg cost of capital

Revenue Growth (7Y)

9.8%

CAGR assumption

EBITDA Margin

34.0%

Steady-state projection

CapEx / Revenue

10.3%

Capital investment

Terminal Growth

4.0%

Long-run growth rate

Projection Period

7 yrs

Explicit forecast horizon

Projected Cash Flows

Values in millions USD

Year	Revenue	EBITDA	FCF	Discounted FCF
Yr 1	5,316	1,520	517	486
Yr 2	5,835	1,784	786	694
Yr 3	6,730	2,200	850	706
Yr 4	7,417	2,574	1,197	934
Yr 5	8,397	3,066	1,425	1,045
Yr 6	8,869	3,299	1,700	1,172
Yr 7	9,343	3,533	1,861	1,205
Terminal Value (PV)				52,237

Key Valuation Ratios

Current vs 5-year average

PE Ratio

33.32x

5Y avg 108.07x

-69.2% vs avg

Forward PE

29.97x

5Y avg 84.75x

-64.6% vs avg

P/FCF Ratio

22.70x

5Y avg 257.16x

-91.2% vs avg

PS Ratio

6.42x

5Y avg 12.52x

-48.7% vs avg

A multiple below its own multi-year average can indicate the stock is cheaper than its recent history — context, not a standalone signal.

Sign in to see the full analysis

The Income Statement, Balance Sheet, Cash Flow, Key Ratios, Forecast, and Fair Value analysis are available to registered users — it's free.

Last Updated

Sep 12, 2026

Short Term

Medium Term

Long Term

Technical Overview

$83.03Price at Analysis

DXCM’s technical profile is mixed in the near term but still constructive on a broader horizon. The stock is sharply oversold and trading near the lower Bollinger Band, yet the short-term backdrop is undermined by a bearish MACD, price below the 20-day MA, and softer volume, which argues for caution rather than aggression. Medium- and long-term structure is healthier: the shares remain above the 50-day and 200-day moving averages, sit in Golden Cross territory, and continue to trade in the upper third of the 52-week range. The most important levels to watch are $82.75 and $82.09 on support, with $84.96 and $92.59 as the key resistance markers.

Short Term

1 to 4 weeks

Downtrend

DXCM’s short-term setup is pressured by price sitting 6.41% below the 20-day MA, a bearish MACD, and contracting relative volume, which suggests the recent move lacks confirmation. RSI at 18.6 and price near the lower Bollinger Band do flag a short-term oversold condition, but that is more consistent with a potential reflex bounce than a durable bullish reversal.

Key Indicators

Price vs 20-day MA-6.41% below

Price vs 50-day MA+0.75% above

RSI (14-day)18.6

RSI InterpretationOversold

MACD TrendNegative (below signal)

Bollinger PositionNear lower band

Volume TrendContracting

Support

$82.75$82.05$80.90

Resistance

$84.96$85.74$86.88

The nearest short-term support is $82.75, just below the current price of $83.03, with deeper supports at $82.05 and $80.9 if selling extends. Resistance is closest at $84.96, then $85.74 and $86.88, and the stock is likely to test $82.75 or $84.96 first within the next 1–4 weeks.

Medium Term

1 to 6 months

Uptrend

The medium-term picture remains constructive because price is still above both the 50-day MA and the 200-day MA, and the stock remains in Golden Cross territory following a recent cross 52 days ago. Although momentum has cooled from the recent highs, the broader trend direction is still up and the stock is holding in the upper portion of its yearly range.

Key Indicators

Price vs 50-day MA+0.75% above

Price vs 200-day MA+16.31% above

52-Week Range PositionUpper third (75%)

Trend DirectionUptrend

MA Cross SignalGolden Cross territory

Relative Volume0.66x avg

Support

$81.56

Resistance

$84.61$86.25$87.51

Weekly support at $81.56 aligns reasonably close to the 50-day MA area, while resistance at $84.61, $86.25, and $87.51 sits below the weekly pivot near $89.3. Over 1–6 months, a retest of the $84.61–$87.51 band looks more probable than a decisive break of $81.56 unless momentum deteriorates materially.

Long Term

6 months and beyond

Uptrend

Over the long term, DXCM remains technically favorable with price 16.31% above the 200-day MA and still positioned in the upper third of its 52-week range. The recent Golden Cross supports an intact structural uptrend, even if the current pullback has temporarily weakened near-term momentum.

Key Indicators

Price vs 200-day MA+16.31% above

52-Week High$92.59

52-Week Low$54.11

Distance from 52w High-10.3%

BB Bandwidth11.5%

MA CrossoverRecent Golden Cross (52 days ago)

Support

$82.09$78.08$74.07

Resistance

$84.57$92.59$95.07

Monthly support at $82.09 and $78.08 defines the broader structural floor, while resistance at $84.57, $92.59, and $95.07 frames the upside into and beyond the prior 52-week high. Over 6+ months, price is more likely to rotate toward the $92.59 high area than to revisit the lower monthly supports, though $82.09 remains the key near-line structural level.

Sign in to see the full analysis

See the full short, medium & long-term indicator breakdowns and support/resistance levels — free for registered users.

Frequently asked questions about DexCom Inc

Does DexCom Inc (DXCM) have an economic moat?: MoatScan AI rates DexCom Inc (DXCM) 62/100 for moat strength, assessed across five sources of competitive advantage: network effects, switching costs, intangible assets, cost advantages and efficient scale. DexCom is one of the strongest franchises in diabetes technology, but its moat is best described as narrow rather than wide.Sign in free to see the Moat Type verdict and the pillar-by-pillar reasoning.
What is DexCom Inc's moat score?: DexCom Inc (DXCM) has a moat score of 62/100. The score is a weighted average of five pillar ratings: network effects, switching costs, intangible assets, cost advantages, and efficient scale. A higher score means the competitive advantages MoatScan AI identifies are wider and more durable.Sign in free to see each pillar rating, the Moat Type verdict and the moat trend.
How does DXCM's share price compare with its estimated fair value?: MoatScan AI estimates DXCM's intrinsic value with a discounted cash flow (DCF) model and shows how that estimate compares with the market price at the time of analysis. The estimate updates with each new financial analysis and is a research estimate, not a recommendation.Sign in free to see the fair value estimate and how it compares with the price.
What is DexCom Inc's fair value estimate?: MoatScan AI derives DexCom Inc's (DXCM) fair value per share from a discounted cash flow (DCF) model built on the company's reported financials, analyst growth forecasts, and a discount rate reflecting its cost of capital. The Financial Analysis tab shows the estimate alongside every assumption behind it.Sign in free to see the estimate and the full assumptions behind it.

Disclaimer: The analysis on this page is generated by AI and is provided for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any security. Always conduct your own due diligence and consult a qualified financial adviser before making any investment decisions. MoatScan AI is an educational research tool. It is not licensed or registered with the Securities Commission Malaysia or any other financial regulator, and it holds no positions in, and receives no compensation from, any company analysed.

DXCM$83.34

Sign in to see the full analysis

Sign in to see the full analysis

Sign in to see the full analysis

Frequently asked questions about DexCom Inc

Other Narrow Moat companies